QUALITY OF LIFE, CLINICAL AND BIOCHEMICAL PARAMETERS IN HYPERTENSIVE PATIENTS WITH COMORBID CONDITIONS
https://doi.org/10.20996/1819-6446-2017-13-1-31-35
Abstract
Aim. To study the socio-behavioral, instrumental and laboratory parameters and quality of life of patients with arterial hypertension (HT) and comorbid conditions.
Material and methods. The study included 64 patients of both sexes, aged 30-69 years. All patients were divided into 3 groups: patients with HT (I group, n=20; 52.7±9.9 years old); patients with HT and diabetes mellitus (DM) type 2 (II group, n=23; 58±5.3 years old); and HT patients with chronic obstructive pulmonary disease (COPD; III group, n=21; 57±7.2 years old). Clinical symptoms, anamnesis, resting heart rate were evaluated as well as blood pressure measurement, echocardiography and biochemical analysis of the blood were performed. Quality of life was also assessed with the international questionnaire EQ-5D.
Results. Combination of HT and COPD was more common in women than in men (66.7% vs 33.3%), and a body mass index >30 kg/m2 was typical for the majority of patients with the HT and DM (34.1±9.1 kg/m2), HT and COPD (33.6±6.7 kg/m2). The assessment with the questionnaire EQ-5D showed that a more pronounced decrease in the quality of life was in patients with HT and DM. Quality of life in groups II and III was worse than in group I (1.7±1.3 and 1.4±1.5 vs 0.9±0.86 scores, respectively). The combinations of HT with DM and HT with COPD were accompanied by increased plasma creatinine levels (88.6±14 and 88.5±11.7 mcmol/L, respectively) and more severe dyslipidemia.
Conclusion. In patients with HT concomitant DM and COPD contribute to the quality of life reduction, increase in plasma creatinine levels, and more severe dyslipidemia.
About the Authors
E. B. Akhmedova
State Research Centre for Preventive Medicine
Russian Federation
Russian Federation
Esmeralda B. Akhmedova - MD, Junior Researcher, Laboratory for the Development of an Interdisciplinary Approach in the Prevention of Chronic Non-Communicable Diseases, Department of Comorbid Conditions Prevention.
Petroverigsky per. 10, Moscow, 101990
B. U. Mardanov
State Research Centre for Preventive Medicine; Domodedovo Central Municipal Hospital
Russian Federation
Russian Federation
Bahodir U. Mardanov - MD, PhD, Cardiologist at Vascular Center, Domodedovo Central Municipal Hospital; Senior Researcher, Laboratory for the Development of an Interdisciplinary Approach in the Prevention of Chronic Non-Communicable Diseases, Department of Comorbid onditions Prevention.
Petroverigsky per. 10, Moscow, 101990; Pirogova ul. 9, Domodedovo, Moscow Region, 142005
K. K. Badeynikova
State Research Centre for Preventive Medicine
Russian Federation
Russian Federation
Ksenia K. Badeynikova - MD, Junior Researcher, Laboratory for the Development of an Interdisciplinary Approach in the Prevention of Chronic Non-Communicable Diseases, Department of Comorbid Conditions Prevention.
Petroverigsky per. 10, Moscow, 101990
M. N. Mamedov
State Research Centre for Preventive Medicine
Russian Federation
Russian Federation
Mehman N. Mamedov - MD, PhD, Professor, Head of Laboratory for the Development of an Interdisciplinary Approach in the Prevention of Chronic Non-Communicable Diseases, Department of Comorbid Conditions Prevention.
Petroverigsky per. 10, Moscow, 101990
References
1. Shalnova S.A., Oganov R.G., Deev A.D. Assessment and management of risk of cardiovascular diseases for the population of Russia. Kardiovaskulyarnaya Terapiya i Profilaktika. 2004; 4: 4-11. (In Russ.) [Шальнова С.А., Оганов Р.Г., Деев А.Д. Оценка и управление риском сердечно-сосудистых заболеваний для населения России. Кардиоваскулярная Терапия и Профилактика. 2004;4:4-11].
2. Arnett D.K., Goodman R.A., Halperin J.L., et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. J Am Coll Cardiol. 2014;64(17):1851-6.
3. International Diabetes Federation 2011. Global Burden: Prevalence and Projections, 2011 and 2030. Available at: http://www.diabetesatlas.org/content/diabetes-and-impairedglucose-tolerance. Checked by December 15, 2016.
4. Kolchin Y.N., Karpenko A.I., Bezuglova S.V. Hyperglycemia at patients with type 2 diabetes mellitus in combination with coronary artery disease. Vnutrennyaya Meditsina. 2007;2(2):42-48. (In Russ.) [Колчин Ю.Н., Карпенко А.И., Безуглова С.В. Гипергликемия у больных сахарным диабетом 2 типа в сочетании с ишемической болезнью сердца. Внутренняя Медицина. 2007;2(2):42-48].
5. Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469-78.
6. Chuchalin A.G. Chronic obstructive pulmonary disease and related disorders. Pulmonologiia. 2008;2:5-14. (In Russ.) [Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Пульмонология. 2008;2:5-14].
7. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73-8.
8. Utsugi H., Nakamura H., Suzuki T., et al. Associations of lifelong cigarette consumption and hypertension with airflow limitation in primary care clinic outpatients in Japan. Respir Investig. 2016;54(1):35-43.
9. Amirjanova V.N., Erdes S. Validation of the Russian version of the general questionnaire EuroQol 5D (EQ-5D). Nauchno-prakticheskaya Revmatologiya. 2007;3:69-75. (In Russ.) [Амирджанова В.Н., Эрдес Ш. Валидация русской версии общего опросника EuroQol 5D (EQ-5D). Научно-практическая Ревматология. 2007;3:69-75].
10. Kotz D., Simpson C.R., Viechtbauer W., et al. Development and validation of a model to predict the 10-year risk of general practitioner-recorded COPD. NPJ Prim Care Respir Med. 2014;24:140-51.
11. Halldin C.N., Doney B.C., Hnizdo E. Changes in prevalence of chronic obstructive pulmonary disease and asthma in the US population and associated risk factors. Chron Respir Dis. 2015;12(1):47-60.
12. Lambert A.A., Putcha N., Drummond M.B., et al. Obesity is Associated with Increased Morbidity in Moderate to Severe COPD. Chest. 2016;pii:S0012-3692(16)57741-1.
13. Nolan C.M., Longworth L., Lord J., et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016;71(6):493-50.
14. Nagorni-Obradovic L.M., Vukovic D.S. The prevalence of COPD co-morbidities in Serbia: results of a national survey. NPJ Prim Care Respir Med. 2014;24:140-8.
Review
For citations:
Akhmedova E.B., Mardanov B.U., Badeynikova K.K., Mamedov M.N. QUALITY OF LIFE, CLINICAL AND BIOCHEMICAL PARAMETERS IN HYPERTENSIVE PATIENTS WITH COMORBID CONDITIONS. Rational Pharmacotherapy in Cardiology. 2017;13(1):31-35. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-1-31-35
Views:
664
.jpg)
Email this article 